SciELO - Scientific Electronic Library Online

 
vol.142 issue5Association between socioeconomic status and oral hygiene among preschoolers enrolled in the IMSS preventive dental program in CampecheSporotrichosis among rural communities in the Northerm Sierra in Puebla: Report of 55 cases September 1995-December 2005 author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Gaceta médica de México

Print version ISSN 0016-3813

Abstract

CARRILLO-ESPER, Raúl et al. Recombinant factor VII activated in non-hemophiliac patients with acute severe hemorrhage in the intensive care unit. Gac. Méd. Méx [online]. 2006, vol.142, n.5, pp. 369-376. ISSN 0016-3813.

Background. Severe hemorrhage is a frequent complication with multiple etiologies and high morbi-mortality observed among critically ill patients. Recombinant Factor VIIa (rFVIIa) constitutes a new therapeutic alternative. Objective. Analyze the evolution in a non-hemophiliac patient group with severe hemorrhage treated with rFVIIa. Material and Methods. Ten non-hemophiliac patients with severe hemorrhage, five men and five women between 18 and 74 years, were included and treated with rFVIIa. We used a t test for statistic analyses. Significance was set at p < 0.001. Results. Among patients treated with rFVIIa, hemorrhage was controlled and the use of blood products was significantly diminished (p < 0.001). Coagulation tests, fibrinogen levels, platelet count and perfusion parameters increased significantly (p < 0.001). Conclusions. rFVIIa is a therapeutic alternative for the treatment of severe hemorrhage not controlled by conventional management.

Keywords : Recombinant Factor VIIa; severe hemorrhage; coagulation cell model.

        · abstract in Spanish     · text in Spanish     · pdf in Spanish